Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces that it has been advised that on 6 October 2017 Adrian Beeston, Non-Executive Director, purchased 317,683 ordinary shares of £0.01 each in the Company (“Ordinary Shares“) at a price of 3.1p per share. Following this transaction Mr Beeston now has an interest in 5,731,969 Ordinary Shares, representing approximately 1.61 per cent. of the Company’s issued share capital.
In addition, the Company has been advised that Peter Redmond, Non-Executive Director, purchased 155,000 Ordinary Shares at a price of 3.135p per share on 6 October 2017. Following this transaction Mr Redmond now has an interest in 5,040,714 Ordinary Shares, representing approximately 1.41 per cent. of the Company’s issued share capital, which includes shares held in the name of Catalyst Corporate Consultants Limited of which Peter Redmond is a director and sole shareholder.
The Notification of Dealing Forms provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Adrian Beeston | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-executive Director | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Hemogenyx Pharmaceuticals Plc | |||
| b) | LEI | n/a | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
| Identification code | ISIN GB00BYX3WZ24 | ||||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 3.1p | 10,000 | ||||
| d) | Aggregated information | ||||
| – Aggregated volume | N/A – single transaction | ||||
| – Price | |||||
| e) | Date of the transaction | 6 October 2017 | |||
| f) | Place of the transaction | London Stock Exchange | |||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||
| a) | Name | Peter Redmond | |||
| 2 | Reason for the notification | ||||
| a) | Position/status | Non-executive Director | |||
| b) | Initial notification /Amendment | Initial notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a) | Name | Hemogenyx Pharmaceuticals Plc | |||
| b) | LEI | n/a | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a) | Description of the financial instrument, type of instrument | Ordinary shares of £0.01 each | |||
| Identification code | ISIN GB00BYX3WZ24 | ||||
| b) | Nature of the transaction | Purchase of Ordinary Shares | |||
| c) | Price(s) and volume(s) | ||||
| Price(s) | Volume(s) | ||||
| 3.135p | 155,000 | ||||
| d) | Aggregated information | ||||
| – Aggregated volume | N/A – single transaction | ||||
| – Price | |||||
| e) | Date of the transaction | 6 October 2017 | |||
| f) | Place of the transaction | London Stock Exchange | |||